ClinicalTrials.gg
CompletedNCT05517421Updated Dec 3, 2025

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

A Phase 3 interventional study of Batoclimab and Placebo in Thyroid Eye Disease, sponsored by Immunovant Sciences GmbH. Completed at 93 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Immunovant Sciences GmbH · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Enrollment
13th of 47
114 · median 84
Started
2022
with 4 others
Phase 3
21 of 53
3 open now
Registered
19th of 53
by date
Lead sponsor
4 of 53
Immunovant Sciences GmbH

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 13th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 in phase 3, and was the 19th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

03

Conditions studied

  • Thyroid Eye Disease

Keywords

  • Batoclimab
  • Thyroid eye disease
  • IMVT-1401
  • Monoclonal antibody
  • Autoimmune disorders
  • Graves' Ophthalmopathy
  • Graves' Orbitopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ≥18 years of age at screening.
  • Have a clinical diagnosis of TED associated with active, moderate to severe TED with the following at screening and Visit 0:

    • A CAS ≥ 4 in either eye, and
    • Clinical evidence of worsened proptosis with:

      1. Proptosis ≥ 18 mm and/or
      2. Proptosis ≥ 3 mm increase from participant's baseline (prior to diagnosis of TED), as estimated by the Investigator/assessor
  • Have moderate to severe active TED, as defined by European Group on Graves' Orbitopathy (EUGOGO) guidelines.
  • Have onset of active TED within 12 months prior to screening.
  • Have documented evidence of detectable anti-TSHR-Ab at screening.
  • Are not expected to require immediate surgical intervention and are not planning corrective surgery/irradiation or medical therapy for TED during the course of the study.
  • Are euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism.

Additional inclusion criteria are defined in the protocol.

Exclusion criteria

Exclusion criteria:

  • Have decreased best corrected visual acuity due to optic neuropathy.
  • Have at least a 2-point decrease in CAS or ≥2 mm decrease in proptosis between screening and Baseline assessments in either eye.
  • Have used any (intravenous or oral) for the treatment of TED or other conditions within 4 weeks prior to screening.
  • Have used any steroid (Intravenous or oral) with a cumulative dose equivalent to ≥ 1 g of methylprednisolone for the treatment of TED.
  • Have known disease other than TED, that, in the opinion of the Investigator, would interfere with the course and conduct of the study.
  • Had previous orbital irradiation or surgery for TED.

Additional exclusion criteria are defined in the protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Batoclimab

    Participants will be administered batoclimab 680 mg SC weekly for 12 weeks followed by 340 mg SC weekly for 12 weeks.

    Drug: Batoclimab

  • Placebo comparator
    Placebo

    Participants will be administered matching placebo SC weekly for 24 weeks.

    Drug: Placebo

Interventions

  • Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

    Also known as: IMVT-1401

  • DrugPlacebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of proptosis responders

    Proptosis is the amount of protrusion of the eye from the orbital rim. Measurements are recorded using the Hertel exophthalmometer. The study eye is defined as the most severely affected eye at the Baseline visit. Proptosis responder is defined as the participant with a greater than or equal to (≥) 2 millimeters (mm) reduction in the study eye without deterioration (≥2 mm increase) in the fellow eye.

    Time frame: At Week 24

Secondary outcomes

  1. Percentage of participants with proptosis ≥2 mm reduction and Clinical Activity Score (CAS) of less than or equal to (≤) 3 from Baseline in the study eye

    The CAS measures the classical signs of acute inflammation (pain, redness, and swelling) in TED. The 7-item scale assigns 1 point for the presence of each of the parameters assessed: spontaneous retrobulbar pain, pain on attempted upward or downward gaze, redness of eyelids, redness of conjunctiva, swelling of caruncle or plica, swelling of eyelids, swelling of conjunctiva (chemosis). The sum of these points is the total score, with 0 indicating no clinical activity and 7 indicating the most severe clinical activity. Higher scores indicate worse symptoms.

    Time frame: Baseline and Week 24

  2. Percentage of participants with CAS of 0 or 1 in the study eye

    Time frame: At Week 24

  3. Mean change from Baseline in CAS in the study eye

    Time frame: Baseline and Week 24

  4. Percentage of participants with positive binding anti-thyroid stimulating hormone receptor (TSHR) antibody (Ab) at Baseline who achieve seroconversion

    Time frame: Baseline and Week 24

  5. Percentage of participants with decrease of at least 1 grade from Baseline in Gorman score for diplopia

    Diplopia will be assessed based on 3 grades: Grade I - Intermittent diplopia (diplopia in primary position of gaze, when tired or when first awakening), Grade II - Inconstant diplopia (diplopia at extremes of gaze) and Grade III - Constant diplopia (continuous diplopia in primary or reading position). Higher scores indicate worse symptoms.

    Time frame: Baseline and Week 24

  6. Mean change from Baseline in proptosis in the study eye

    Time frame: Baseline and Week 24

  7. Percentage of participants with ≥6-point increase from Baseline in total Graves' ophthalmopathy - Quality of life (GO-QOL) score

    The GO-QOL is a 16-item self-administered questionnaire designed to assess how GO affects different aspects related to quality of life (visual functioning and psychosocial consequences). The points given to questions 1 to 8 and 9 to 16 are added to obtain 2 raw scores ranging from 8 to 24; one for visual functioning and one for appearance. Higher scores indicate better outcome.

    Time frame: Baseline and Week 24

  8. Percentage of participants with ≥8-degree increase from Baseline in motility (in at least 1 of 4 directions) in the study eye

    Time frame: Baseline and Week 24

07

Study locations

93 sites
  • Site Number - 1557
    Beverly Hills, California 90210, United States
  • Site Number - 1539
    Carlsbad, California 92011, United States
  • Site Number - 1502
    Los Angeles, California 90025, United States
  • Site Number - 1505
    Los Angeles, California 90033, United States
  • Site Number - 1532
    Los Angeles, California 90255, United States
  • Site Number - 1537
    San Diego, California 92108, United States
  • Site Number - 1531
    Torrance, California 90505, United States
  • Site Number - 1501
    Aurora, Colorado 80045, United States
  • Site Number - 1544
    Longmont, Colorado 80503, United States
  • Site Number - 1547
    Newark, Delaware 19713, United States
  • Site Number - 1504
    Miami, Florida 33136, United States
  • Site Number - 1538
    Port Charlotte, Florida 33952, United States
  • Site Number - 1542
    Tampa, Florida 33603, United States
  • Site Number - 1536
    West Palm Beach, Florida 33401, United States
  • Site Number - 1554
    Stockbridge, Georgia 30281, United States
  • Site Number - 1534
    Chicago, Illinois 60610, United States
  • Site Number - 1545
    Iowa City, Iowa 52242, United States
  • Site Number - 1535
    Baltimore, Maryland 21231, United States
  • Site Number - 1506
    Boston, Massachusetts 02130, United States
  • Site Number - 1540
    Las Vegas, Nevada 89184, United States
  • Site Number - 1530
    Chapel Hill, North Carolina 27517, United States
  • Site Number - 1550
    Columbus, Ohio 43215, United States
  • Site Number - 1507
    Portland, Oregon 97232, United States
  • Site Number - 1556
    Warwick, Rhode Island 02886, United States
  • Site Number - 1551
    Dallas, Texas 75231, United States
  • Site Number - 1508
    Houston, Texas 77030, United States
  • Site Number - 1558
    Mesquite, Texas 75149, United States
  • Site Number - 1500
    Roanoke, Virginia 24018, United States
  • Site Number - 1509
    Madison, Wisconsin 53705, United States
  • Site Number - 2502
    Edmonton, Alberta T6G 2E1, Canada
  • Site Number - 2500
    Ottawa, Ontario K1H 8L6, Canada
  • Site Number - 2501
    Montreal, Quebec H1T 2M4, Canada
  • Site Number - 3452
    Tbilisi, 0101, Georgia
  • Site Number - 3454
    Tbilisi, 0114, Georgia
  • Site Number - 3455
    Tbilisi, 0114, Georgia
  • Site Number - 3450
    Tbilisi, 0159, Georgia
  • Site Number - 3451
    Tbilisi, 0159, Georgia
  • Site Number - 3453
    Tbilisi, 0186, Georgia
  • Site Number - 6609
    Tübingen, Baden - Wuttemberg 72076, Germany
  • Site Number - 6608
    Frankfurt am Main, Hesse 60318, Germany
  • Site Number - 6604
    Mainz, Rhineland-Palatinate 55131, Germany
  • Site Number - 6610
    Leipzig, Saxony 04103, Germany
  • Site Number - 6611
    Schwerin, 19049, Germany
  • Site Number - 4764
    Afula, 1834111, Israel
  • Site Number - 4761
    Jerusalem, 91120, Israel
  • Site Number - 4763
    Nahariya, 2210000, Israel
  • Site Number - 4762
    Petah Tikva, 4941492, Israel
  • Site Number - 4760
    Ramat Gan, 5265601, Israel
  • Site Number - 6206
    Bologna, 40138, Italy
  • Site Number - 6207
    Catania, CAP95125, Italy
  • Site Number - 6204
    Milan, 20122, Italy
  • Site Number - 6203
    Milan, 20149, Italy
  • Site Number - 6205
    Naples, 80131, Italy
  • Site Number - 6209
    Palermo, 90127, Italy
  • Site Number - 6200
    Pisa, 56100, Italy
  • Site Number - 6201
    Pisa, 56124, Italy
  • Site Number - 6202
    Roma, 00189, Italy
  • Site Number - 6208
    Rome, 00161, Italy
  • Site Number - 7415
    Maebashi, Gunma 371-8511, Japan
  • Site Number- 7418
    Hokkaido, Sapporo 060-8648, Japan
  • Site Number - 7401
    Fukuoka, 812-0011, Japan
  • Site Number - 7403
    Hyōgo, 663-8501, Japan
  • Site Number - 7411
    Ibaraki, 305-8576, Japan
  • Site Number - 7410
    Kanagawa, 230-8765, Japan
  • Site Number - 7402
    Kitakyushu, 807-8556, Japan
  • Site Number - 7417
    Kobe, 657-0068, Japan
  • Site Number - 7416
    Kumamoto, 860-8556, Japan
  • Site Number - 7414
    Miyazaki, 889-1692, Japan
  • Site Number - 7407
    Nagasaki, 852-8501, Japan
  • Site Number - 7406
    Nagoya, 467-8602, Japan
  • Site Number - 7412
    Nankoku, 783-0043, Japan
  • Site Number - 7408
    Osaka, 545-0051, Japan
  • Site Number - 7409
    Tokyo, 173-8610, Japan
  • Site Number - 7404
    Tottori, 683-8504, Japan
  • Site Number - 7413
    Yamaguchi, 754-0002, Japan
  • Site Number - 3107
    Gliwice, 44-102, Poland
  • Site Number - 3103
    Katowice, 40-514, Poland
  • Site Number - 3101
    Krakow, 30-688, Poland
  • Site Number - 3104
    Lublin, 20-171, Poland
  • Site Number - 3102
    Lublin, 20-562, Poland
  • Site Number - 3105
    Lublin, 60-354, Poland
  • Site Number - 3106
    Olsztyn, 10-561, Poland
  • Site Number - 3100
    Warsaw, 02-097, Poland
  • Site Number - 7305
    Guildford, GU2 7XX, United Kingdom
  • Site Number - 7310
    Hull, HU6 7RX, United Kingdom
  • Site Number - 7309
    Leicester, LE15WW, United Kingdom
  • Site Number - 7303
    London, EC1V 2PD, United Kingdom
  • Site Number - 7311
    London, SE17EH, United Kingdom
  • Site Number - 7312
    London, W1T 6AH, United Kingdom
  • Site Number - 7313
    London, W1T 7HA, United Kingdom
  • Site Number - 7300
    Manchester, M139WL, United Kingdom
  • Site Number - 7302
    Newcastle upon Tyne, NE1 3BZ, United Kingdom
  • Site Number - 7308
    Sheffield, S102SB, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Nov 2025, 35 months.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 26, 2022
StartActual
Nov 23, 2022
Primary completionActual
Nov 2, 2025
CompletionActual
Nov 18, 2025
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05517421
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Nov 23, 2022
Primary completion
Nov 2, 2025
Completion
Nov 18, 2025
Last update
Dec 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion